Abstract 697P
Background
Beta-blockers have been associated with improved survival and immune checkpoint inhibitors (ICI) efficacy in cancer patients. We aimed to evaluate whether BB has an impact on outcomes of mRCC patients treated with N.
Methods
The multicentric and prospective study NIVOREN GETUG AFU 26 evaluated the safety and efficacy of N in mRCC patients after failure of 1 or 2 tyrosine kinase inhibitors. Patients were treated between February 2016 and June 2017. Patients who were treated with BB at N start were compared with those who did not. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and toxicities were assessed. Multivariate Cox analysis was used to adjust for age and BMI.
Results
Overall, 698 patients were enrolled. One hundred and fifty-seven (22.5%) patients were treated with BB. From these, 143 (91.1%) received β1-selective blocker and 14 (8.9%) received pan β-blocker. Clinical characteristics were similar between both groups, except for median age and BMI (Table). Median OS was 22.8 (95%CI: 17.5-28.7; 82 events) months for BB users versus 24.1 (95%CI: 20.7-27.8; 263 events) months in non-users [HR 1.07 (0.83-1.37), p=0.6004]. Median PFS was 3.8 (95%CI: 2.8-5.2; 133 events) months in BB users versus 3.1 (95%CI: 2.8-4.4; 455 events) months in non-users [HR 0.99 (0.82-1.20), p=0.9409]. In multivariate analysis, both endpoints were not associated to BB at nivolumab start. The groups did not differ for ORR: 20.0% for BB users versus 20.1% for BB non-users (p=0.975). Toxicity was similar between groups. Table: 697P
Patient characteristics
| ALL (n=698) | BB (n=157) | No BB (n=541) | ||
| Age(year) | Median (range) | 64 (22; 90) | 68 (33; 86) | 62 (22; 90) |
| Gender–no(%) | Male | 540 (77) | 123 (78) | 417 (77) |
| BMI–no(%) | <25 kg/m 2 | 333 (49) | 62 (40) | 271 (51) |
| ≥25 kg/m 2 | 353 (51) | 94 (60) | 259 (49) | |
| Missing | 12 | 1 | 11 | |
| Histology–no(%) | Clear Cell | 695 (100) | 157 (100) | 538 (100) |
| Missing | 3 | 0 | 3 | |
| IMDC score–no(%) | Good | 126 (18) | 28 (18) | 98 (18) |
| Intermediate | 391 (56) | 91 (58) | 300 (56) | |
| Poor | 179 (26) | 38 (24) | 141 (26) | |
| Missing | 2 | 0 | 2 | |
| ECOG PS–no(%) | ≥2 | 102 (16) | 23 (15) | 79 (15) |
| Missing | 36 | 7 | 29 | |
| Previous lines–no(%) | 1-2 | 541 (78) | 119 (76) | 422 (78) |
| ≥3 | 157 (22) | 38 (24) | 119 (22) |
Conclusions
There is no impact of BB in mRCC patients treated with N in our study.
Clinical trial identification
NCT03013335.
Editorial acknowledgement
Legal entity responsible for the study
Unicancer.
Funding
Institut National du Cancer, Direction Générale de l’Offre de Soins, Bristol-Myers-Squibb.
Disclosure
E. Colomba: Financial Interests, Personal, Invited Speaker: Ipsen, Sanofi, BMS and Pfizer. B. Escudier: Financial Interests, Personal and Institutional, Advisory Role: Bristol-Myers Squibb, Bristol-Myers Squibb, Ipsen, Roche , Pfizer, Oncorena, Aveo. L. Albiges: Financial Interests, Personal and Institutional, Advisory Role: Novartis, Amgen (Inst), Bristol-Myers Squibb, Bristol-Myers Squibb (Inst), Ipsen (Inst), Roche (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst), Merck (Inst). All other authors have declared no conflicts of interest.